Why the study?
The effects of sacubitril/valsartan on renal pathophysiology, including in diabetic kidney disease, remained unclarified.
Does sacubitril/valsartan ameliorate renal tubulointerstitial injury in a mouse model of type 2 diabetes with aldosterone excess?
Population
Eight-week-old male db/db mice fed a high-salt diet
Comparison
ALDO + SAC/VAL vs ALDO, ALDO + VAL, and HSD control
Design
Animal experimental study
Follow-up
4 weeks
Key result
In a mouse model of type 2 diabetes with aldosterone excess, sacubitril/valsartan increased renal plasma flow and GFR, and ameliorated tubulointerstitial fibrosis compared to aldosterone alone.
Authors
Loading...
SAC/VAL ameliorates tubulointerstitial injury via increased renal plasma flow in aldosterone-exposed diabetic mice; hypothesis-generating for human DKD.
Does sacubitril/valsartan ameliorate renal tubulointerstitial injury in a mouse model of type 2 diabetes with aldosterone excess?
Sacubitril/valsartan ameliorates renal tubulointerstitial fibrosis and improves renal hemodynamics in a diabetic mouse model with aldosterone excess, suggesting renoprotective effects beyond AT1 receptor blockade.
Nishio et al. (2023) studied Type 2 diabetes with aldosterone excess (mouse model). Sacubitril/valsartan vs. Aldosterone alone or Aldosterone + Valsartan was evaluated on Plasma ANP levels, renal histology, and haemodynamic parameters (GFR and RPF). In a mouse model of type 2 diabetes with aldosterone excess, sacubitril/valsartan increased renal plasma flow and GFR, and ameliorated tubulointerstitial fibrosis compared to aldosterone alone.